Effective screening modalities are currently available for only a small subset of cancers, and
they generally have suboptimal performance with complicated procedures. Therefore, there …

Given that cancer mortality is usually a result of late diagnosis, efforts in the field of early
detection are paramount to reducing cancer-related deaths and improving patient outcomes …

An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Hepatocellular carcinoma (HCC) is among the leading causes of worldwide cancer‐related
morbidity and mortality. Poor prognosis of HCC is attributed primarily to tumor presentation …

The analysis of circulating tumor cells (CTCs) is an outstanding tool to provide insights into
the biology of metastatic cancers, to monitor disease progression and with potential for use …

Circulating tumor DNA (ctDNA) in fluids has gained attention because ctDNA seems to
identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of …

Circulating tumor DNA holds substantial promise as an early detection biomarker,
particularly for cancers that do not have currently accepted screening methodologies, such …

Liquid biopsies hold the potential to inform cancer patient prognosis and to guide treatment
decisions at the time when direct tumor biopsy may be impractical due to its invasive nature …

Triple-negative breast cancer (TNBC) is an aggressive breast type of cancer with no
expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal …

Cancer genomes have been explored from the early 2000s through massive exome
sequencing efforts, leading to the publication of The Cancer Genome Atlas in 2013 …